Therapeutic strategies for COVID-19 patients: An update

医学 大流行 洛比那韦 临床试验 2019年冠状病毒病(COVID-19) 利托那韦 药理学 重症监护医学 免疫学 病毒学
作者
Muhammad Ibrahim Getso,Soudabeh Etemadi,Vahid Raissi,Moein Mohseni,Maedeh Sadat Mohseni,Farid Raeisi,Omid Raiesi
出处
期刊:Infectious disorders drug targets [Bentham Science]
卷期号:22
标识
DOI:10.2174/1871526522666220322145729
摘要

The novel coronavirus SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread causing a global pandemic that infected more than 444 million people, resulting in severe social and economic ramifications, and claimed more than 6,010,000 lives by March 5, 2022. The pandemic attracted global attention with consequential multiple economic, social, and clinical studies. Among causes of poor clinical outcome of the disease are therapeutic challenges, leading to spirals of studies in search for better therapeutic alternatives. Despite the worsening circumstances of the pandemic, no drug has yet shown remarkable efficacy in the clinical management of COVID-19 patients in large-scale trials. Many potential therapeutic strategies, including the use of nucleotide analogs, chloroquine phosphate, arbidol, protease inhibitors (lopinavir/ritonavir), plasma, monoclonal antibodies, plastic antibodies based on Molecularly Imprinted Polymers (MIPs), traditional Chinese medicine (TCM), nanomaterials, vaccine, and mesenchymal stem cells (MSCs), have emerged with various degrees of successes. Remdesivir and dexamethasone have now been licensed based on the results of randomized controlled trials. Baricitinib, the Janus kinase (JAK) 1/2 inhibitor, is also an attractive candidate due to its properties as a potent anti-inflammatory agent and its hypothesized off-target antiviral effects against SARS-CoV-2. Besides, human plasma from recovered COVID-19 patients is theoretically expected to be safe and effective for both therapy and post-exposure prophylaxis. In light of the literature, the correlation between the reduction of C5aR1/C5aR2 and IL6-IL6R axis, using the available anti-IL6R mAb would be crucial. More, MSCs are a potential therapeutic choice for patients with COVID-19 pneumonia. The coronavirus spike (S) protein that mediates the process of the infection via binding of host cells to the virus receptor is an essential focus for vaccine development. Importantly, with the number of patients increasing daily, there is an urgent need for effective therapeutic intervention. In this review, we expatiated on several strategies deployed for the treatment of COVID-19 infection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
05完成签到 ,获得积分10
4秒前
4秒前
Josie完成签到 ,获得积分10
7秒前
caozhi完成签到,获得积分10
7秒前
廖无极完成签到 ,获得积分10
8秒前
zzy完成签到 ,获得积分10
11秒前
hhehe发布了新的文献求助10
13秒前
π1完成签到 ,获得积分10
14秒前
无限的山水完成签到,获得积分10
17秒前
Chen完成签到 ,获得积分10
20秒前
香蕉觅云应助xiaodong采纳,获得10
25秒前
朴素的梦岚完成签到,获得积分10
27秒前
34秒前
妮妮完成签到 ,获得积分10
35秒前
程大大大教授完成签到,获得积分10
37秒前
科研铁人完成签到 ,获得积分10
37秒前
不知名研究生完成签到,获得积分10
38秒前
xiaodong发布了新的文献求助10
38秒前
jbear完成签到 ,获得积分10
43秒前
之贻完成签到,获得积分10
44秒前
45秒前
红星路吃饼子的派大星完成签到 ,获得积分10
48秒前
xiaodong完成签到,获得积分10
49秒前
qazx完成签到,获得积分10
50秒前
搬砖工完成签到,获得积分10
56秒前
稳重的峻熙完成签到,获得积分10
58秒前
1分钟前
cometx完成签到 ,获得积分10
1分钟前
qq发布了新的文献求助10
1分钟前
orixero应助博修采纳,获得10
1分钟前
刘孝鹏完成签到,获得积分10
1分钟前
和平完成签到 ,获得积分10
1分钟前
Ploaris完成签到 ,获得积分10
1分钟前
航行天下完成签到 ,获得积分10
1分钟前
单薄的英姑完成签到 ,获得积分10
1分钟前
PeterBeau完成签到 ,获得积分10
1分钟前
qq完成签到,获得积分10
1分钟前
1分钟前
巴啦啦小魔仙完成签到 ,获得积分10
1分钟前
Jingyi完成签到 ,获得积分10
1分钟前
高分求助中
Rock-Forming Minerals, Volume 3C, Sheet Silicates: Clay Minerals 2000
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
The Healthy Socialist Life in Maoist China 600
The Vladimirov Diaries [by Peter Vladimirov] 600
encyclopedia of computational mechanics,2 edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3268841
求助须知:如何正确求助?哪些是违规求助? 2908247
关于积分的说明 8345239
捐赠科研通 2578647
什么是DOI,文献DOI怎么找? 1402212
科研通“疑难数据库(出版商)”最低求助积分说明 655381
邀请新用户注册赠送积分活动 634500